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A B S T R A C T   
Potential therapeutic approaches in coronavirus disease 2019 (COVID-19) comprise antiviral and im-
munomodulatory agents; however, no immunomodulator drug has been approved. This multicenter, prospective, 
open-label, uncontrolled study aimed to assess the use of subcutaneous tocilizumab in adult patients with severe and 
critical COVID-19. Tocilizumab was added to the standard care of therapy at a dose of 324 mg (< 100 kg body-
weight) or 486 mg (≥100 kg bodyweight). The study endpoints were all-cause mortality rate, changes in oxygen- 
support level, oxygen saturation, body temperature, respiratory rate, and laboratory variables during the study, and 
drug safety. Of 126 patients enrolled, 86 had severe and 40 had critical disease. Most patients were male (63.49%) 
and aged below 65 (78.57%). By day 14 of the study, 4.65% (4/86) of severe patients and 50.00% (20/40) of critical 
patients died. By the end, 6.98% (6/86) of severe patients and 60.00% (24/40) of critical patients died. Outcomes 
concerning three additional endpoints (oral temperature, oxygen saturation, and respiratory rate) were significantly 
improved as early as three days after tocilizumab administration in both groups of subjects, more considerably in 
severe patients. Significant improvement in the required level of oxygenation was reported in severe patients seven 
days after tocilizumab administration. No tocilizumab-related serious adverse event occurred in this study. 
Subcutaneous tocilizumab might improve some clinical parameters and reduce the risk of death in COVID-19 pa-
tients, particularly if used in the early stages of respiratory failure.   
https://doi.org/10.1016/j.intimp.2020.107102 
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1. Introduction 
The coronavirus disease 2019 (COVID-19) pandemic, caused by the 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is 
causing significant morbidity and mortality around the world. Similar 
to SARS-CoV and Middle East respiratory syndrome coronavirus 
(MERS-CoV), SARS-CoV-2 belongs to the genus betacoronavirus and is 
an enveloped, positive-strand RNA virus [1]. Respiratory droplet 
Fig. 1. Activation of pathogenic T cells and inflammatory monocytes following SARS-CoV-2 infection and the mechanism of action of tocilizumab. Tocilizumab 
inhibits sIL-6R and mIL-6R-mediated signaling and can potentially improve the clinical outcomes in severe COVID-19. ARDS, acute respiratory distress syndrome; 
GM-CSF, granulocyte-macrophage colony-stimulating factor; gp130, glycoprotein 130; IL-6, interleukin 6; mIL-6R, membrane-bound IL-6 receptor; sIL-6R, soluble IL- 
6 receptor; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. 
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transmission from infected patients is known to be the main route of 
COVID-19 transmission to the community [2]. According to the latest 
world health organization (WHO) COVID-19 epidemiological update, 
over 34.8 million cases were confirmed by national authorities by 10:00 
central European summer time (CEST), 05 October 2020, and this 
number is fast increasing. Since the beginning of the pandemic in De-
cember 2019, the global mortality rate of COVID-19 was 2.96% (over 
1,030,000 deaths). The Americas is the most affected region accounting 
for 49% of global cases and 55% of cumulative deaths [3]. Although 
most patients experience either asymptomatic infection or non-severe 
disease, a large number of patients die due to complications such as 
multiple organ failure, severe pneumonia, acute respiratory distress 
syndrome (ARDS), heart failure, arrhythmias, renal failure, and septic 
shock [4,5]. Studies in China [6–8] and Italy [9,10] found that older 
age, male sex, smoking, and comorbidities such as respiratory diseases, 
diabetes, hypertension, and cardiovascular diseases are risk factors as-
sociated with severe disease and death in patients with COVID-19. 
In asymptomatic and paucisymptomatic patients, controlled and 
effective host immune response suppresses viral load. However, in 
medically complicated patients, immune evasion and rapid replication 
of SARS-CoV-2 can be followed by a dysregulated immune response and 
extensive release of inflammatory mediators [11]. In these patients, the 
combination of direct destruction of virus-infected cells and indirect 
destruction via hyperinflammatory response leads to lung epithelium 
damage and unfavorable clinical outcomes [12]. Accordingly, potential 
therapeutic approaches comprise antiviral agents to eradicate SARS- 
CoV-2 (such as remdesivir, lopinavir/ritonavir, and favipiravir) and 
immunomodulator agents (such as tocilizumab, dexamethasone, and 
interferon beta) to dampen inflammation by modulating proin-
flammatory cytokines [13]. Many treatments are being investigated in 
COVID-19 clinical trials, yet only a few are approved by regional au-
thorities. By 05 October 2020, remdesivir was the only approved 
treatment by the Therapeutic Goods Administration (TGA) in Australia  
[14], the European Medicines Agency (EMA) [15], and the Pharma-
ceuticals and Medical Devices Agency (PMDA) in Japan [16]. The 
United States Food and Drug Administration (U.S. FDA) also has issued 
an emergency use authorization (EUA) to permit the emergency use of 
this unapproved antiviral product [17]. Moreover, the National In-
stitutes of Health (NIH) and EMA’s human medicines committee 
(CHMP) recommend the use of dexamethasone in COVID-19 patients 
who require oxygen support [18,19]. 
Several studies have documented increased serum levels of a wide 
range of cytokines such as tumor necrosis factor-alpha (TNF-α), inter-
feron-gamma (IFN-γ), granulocyte-macrophage colony-stimulating 
factor (GM-CSF), interleukin (IL)-2, IL-4, IL-6, and IL-10 in COVID-19 
patients, with significantly higher levels in severe to critical cases  
[7,20–23]. Infection with SARS-CoV-2 results in the activation of CD4+ 
T cells to become GM-CSF-expressing pathogenic T helper (Th) 1 cells  
[24]. Abnormally high levels of activated Th17 cells are also observed 
in severe- to critically-ill COVID-19 patients, which can take part in the 
extensive release of inflammatory mediators such as IL17, GM-CSF, 
IL21, and IL22 [23,25]. This cytokine environment results in the gen-
eration of inflammatory CD14+CD16+ monocytes with high expres-
sion of IL-6 [24]. IL-6 has the capability to induce the development of 
Th17 cells and plays a major role in the COVID-19-associated hyper-
inflammation [26,27]. A meta-analysis comparing IL-6 levels between 
patients with noncomplicated and complicated COVID-19 (six studies; 
1302 patients) found 2.9-fold higher levels in the latter group [28]. 
Moreover, a clinical investigation found substantially higher levels of 
IL-6 in the endotracheal aspirates of COVID-19 patients, compared to 
their blood samples [29]. This indicates a compartmental inflammation 
in COVID-19 patients, with a distinctly higher presence of inflammatory 
mediators in the lung compartment (Fig. 1). 
In order to restrain the overactivity of the immune system and ex-
cessive inflammation, different classes of immune-based therapies are 
being explored in COVID-19 clinical trials, including IL-6 inhibitors, IL- 
1 inhibitors, corticosteroids, Janus kinase inhibitors, and COVID-19 
convalescent plasma [30,31]. Tocilizumab is a recombinant humanized 
IL-6 receptor antagonist. This monoclonal antibody is approved by the 
U.S. FDA in severe or life-threatening cytokine release syndrome (in-
duced by chimeric antigen receptor (CAR) T-cell therapy) [32], rheu-
matoid arthritis [33], giant cell arteritis [34], polyarticular juvenile 
idiopathic arthritis [35], and systemic juvenile idiopathic arthritis [36]. 
In COVID-19 patients, the blockage of the IL-6 receptor by tocilizumab 
could potentially reduce the cytokine release and acute phase reactant 
production, hence, alleviating the symptoms and improving the clinical 
outcomes. Besides several case reports, a number of published studies 
including four retrospective cohort studies [22,37–39], two prospective 
open-label studies [40,41], and a case series [42], the preliminary re-
sults of a randomized controlled trial (#NCT04331808) [43], and the 
results of two meta-analysis studies [44,45] (risk ratios [RRs] of 0.45 
and 0.73, 95% confidence intervals [CIs] of 0.38–0.55 and 0.57–0.93, 
respectively) support the use of tocilizumab for severe COVID-19. By 
contrast, in one other meta-analysis [46], the beneficial impact of to-
cilizumab on COVID-19 mortality did not reach statistical significance 
(RR of 0.62, 95% CI of 0.31–1.22), and data from these studies are 
conflicting. 
We conducted a multicenter prospective study in patients with se-
vere or critical COVID-19 to assess the outcomes following sub-
cutaneous tocilizumab treatment. This relatively large study would 
improve the data available on the use of subcutaneous tocilizumab in 
COVID-19 patients. Moreover, this study’s results could help determine 
the proper timing for the administration of tocilizumab, based on the 
severity of the disease. 
2. Patients and methods 
2.1. Study design 
This multicenter, prospective, open-label, uncontrolled study was 
performed in eight tertiary care centers in Iran, between 15 March and 
22 June 2020. The study was approved by the research ethics com-
mittee at the National Institution for Medical Research Development, 
#IR.NIMAD.REC.1398.414. The trial was registered at the Iranian 
Registry of Clinical Trials (IRCT.ir), #IRCT20150303021315N17. 
2.2. Study population 
We assessed all adult COVID-19 patients’ eligibility with a con-
firmed diagnosis of SARS-CoV-2 infection either by polymerase chain 
reaction (PCR) or by computed tomography (CT) of the chest. We in-
cluded patients with fever defined as an oral temperature of 37.8 °C 
(100°F) or higher, cough, shortness of breath, or respiratory rate of 
more than 30 breaths per minute that had a peripheral blood oxygen 
saturation (SpO2) of 93% or less in room air and a serum IL-6 level of 
three times upper limit of normal or higher. We excluded patients with 
a known hypersensitivity to tocilizumab or any other component of the 
formulation, history of infection with hepatitis B virus (HBV), hepatitis 
C virus (HCV), human immunodeficiency virus (HIV), history of im-
munodeficiency, hepatic disorders, bone marrow suppression defined 
as absolute neutrophil count (ANC) below 2000/mm3 or platelet count 
below 100,000/mm3, active peptic ulcer, active diverticulitis, or any 
other gastrointestinal disorders that increase the risk of gastrointestinal 
perforation, pregnancy, breast-feeding, any concurrent active infection 
other than COVID-19, and severe renal impairment defined as a glo-
merular filtration rate (GFR) of below 30 mL/min/1.73 m2. All subjects 
enrolled met the criteria for severe disease defined by the Report of the 
WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)  
[47], published on 28 February 2020, as tachypnoea (30 breaths/ 
minute or more), resting oxygen saturation of 93% or less, or a ratio of 
arterial oxygen partial pressure to fractional inspired oxygen (PaO2/ 
FIO2) of below 300 mmHg. Patients with respiratory failure requiring 
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mechanical ventilation, shock, or other organ failure requiring transfer 
to the intensive care unit (ICU) were considered critical. All patients or 
their legal guardians provided written informed consent prior to the 
administration of tocilizumab. 
2.3. Study interventions 
Patients received subcutaneous injections of tocilizumab (AryoGen 
Co., Iran) at a dose of 324 mg (as two simultaneous 162 mg injections) 
for patients weighing < 100 kg and at a dose of 486 mg (as three si-
multaneous 162 mg injections) for patients weighing 100 kg or more 
along with the standard-of-care (SOC) treatment in each study center. 
SOC treatment included supportive care, antiviral agents, hydroxy-
chloroquine, subcutaneous interferon beta-1a, and antibiotic agents. 
2.4. Study outcomes 
We followed up patients until hospital discharge or death. Our 
primary outcome was all-cause mortality rate during the hospital stay. 
As secondary outcomes, we evaluated changes in SpO2, body tem-
perature, respiratory rate, and laboratory values, including serum levels 
of C-reactive protein (CRP) and white blood cell (WBC) count from 
baseline through the last day of hospital stay. In addition, we assessed 
the change in patients’ required oxygen-support class based on a six- 
point ordinal scale. The scale consists of the following steps: 1, no 
supplemental oxygen; 2, nasal catheter oxygen inhalation; 3, mask 
oxygen inhalation; 4, noninvasive positive pressure ventilation; 5, in-
vasive mechanical ventilation; and 6, death. Adverse events were 
monitored and reported throughout the study. 
2.5. Statistical analysis 
Demographic data were presented with descriptive statistics, and 
categorical variables were compared using the chi-square test. 
Continuous variables were expressed as median (IQR). Between-group 
differences were analyzed using the Mann-Whitney U test, and within- 
group changes during the study were analyzed using the Wilcoxon 
signed-rank test. Mortality rates were expressed as numbers (%), and 
Kaplan-Meier curves were used to plot the survival data. Log-rank test 
was used to analyze the statistical significance of survival differences 
between severe and critical patients. Statistical analyses were 
performed using STATA version 14.0 (Stata Corporation, Texas, USA) 
and R version 3.6.3 (R Foundation for Statistical Computing, Vienna, 
Austria). P-values  <  0.05 were considered as statistically significant. 
3. Results 
3.1. Baseline characteristics 
A total of 126 COVID-19 patients including 86 patients with severe 
disease and 40 patients with critical disease were included in this study. 
Most patients were male (63.49%, 80/126) and non-elderly, aged 
below 65 years (78.57%, 99/126). The mean (SD) and median (range) 
age was 53.49 (13.26) and 55 (20–85) years. Demographic character-
istics of patients were similar in severe and critical patients (table 1). 
On admission, median (IQR) oral temperature (37.10 °C (36.80–38.00) 
vs. 37.70 °C (37.00–39.00), p-value = 0.08), respiratory rate (20.00 
breaths/min (19.00–24.00) vs. 24.00 breaths/min (20.00–26.00), p- 
value = 0.07), heart rate (89.00 beats/min (82.00–100.00) vs. 97.50 
beats/min (80.00–110.00), p-value = 0.23), and mean arterial pressure 
(87.50 mmHg (83.33–96) vs. 97.50 mmHg (90–108.33), p-value  <  
0.001) were higher in critical patients. Baseline values of laboratory 
measurements are provided in table 1. Most notably, the initial levels of 
WBC counts (6.90 k/mm3 (5.15–9.08) vs. 10.30 k/mm3 (8.30–13.60), 
p-value  <  0.001) and CRP (22.00 mg/L (6.00–39.00) vs. 48.00 mg/L 
(6.00–85.20), p-value = 0.097) were higher in critical patients. 
3.2. Mortality 
The median (IQR) length of hospital stay, from tocilizumab ad-
ministration until discharge home or death, was 8 days (5–12) (7 days 
(5–11) in severe patients and 10 days (5.5–14) in critical patients). 
Individual patient’s length of hospital stay and final status (death or 
discharge) are provided in Fig. A1. By day 14, 68.25% (86/126) of 
patients were discharged alive from hospital (87.21% (75/86) of severe 
patients and 27.5% (11/40) of critical patients), 19.05% (24/126) died 
(4.65% (4/86) of severe patients and 50.00% (20/40) of critical pa-
tients), and 12.70% (16/126) were still hospitalized (8.14% (7/86) of 
severe patients and 22.5% (9/40) of critical patients). By the end, 
76.19% (96/126) of patients were discharged alive from the hospital. 
Of the 86 severe patients, 6 (6.98%) died, while, of the 40 critical pa-
tients, 24 (60.00%) died in the hospital. The risk of death was 
Table 1 
Baseline patient characteristics. Data are median (IQR) or n (%). ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; INR, 
international normalized ratio; MAP, mean arterial pressure; sCr, serum creatinine; PTT, partial thromboplastin time; WBC, white blood cell.       
Severe (N = 86) Critical (N = 40) Total (N = 126)  
Age (year) 53.50 (45.50–62.00) 57.50 (50.00–63.50) 55.00 (46.00–63.00)  
< 65 67 (77.91) 32 (80.00) 99 (78.57) 
Weight (kg) 75.00 (70.00–80.00) 80.00 (68.50–94.00) 77.00 (70.00–85.00)  
> 100 3 (3.49) 3 (7.50) 6 (4.76) 
Sex: Female 32 (37.21) 14 (35.00) 46 (36.51) 
WBC (k/mm3) 6.90 (5.15–9.08) 10.30 (8.30–13.60) 7.92 (5.79–11.07) 
CRP (mg/L) 22.00 (6.00–39.00) 48.00 (6.00–85.20) 24.00 (6.00–46.00) 
ALT (IU/L) 36.50 (24.50–62.00) 46.00 (28.00–61.00) 37.50 (26.00–61.00) 
AST (IU/L) 35.00 (25.00–49.00) 49.00 (36.00–82.00) 38.50 (27.50–62.00) 
sCr (mg/dL) 1.00 (0.90–1.10) 1.10 (0.90–1.20) 1.00 (0.90–1.20) 
PTT (s) 38.00 (30.00–43.00) 36.00 (34.00–39.00) 36.00 (31.00–43.00) 
INR 1.14 (1.07–1.23) 1.29 (1.19–1.40) 1.19 (1.08–1.30) 
MAP (mmHg) 87.50 (83.33–96.00) 97.50 (90.00–108.33) 93.33 (83.33–98.33) 
Respiratory Rate (breaths/min) 20.00 (19.00–24.00) 24.00 (20.00–26.00) 20.00 (19.00–26.00) 
Oral temperature (°C) 37.10 (36.80–38.00) 37.70 (37.00–39.00) 37.10 (36.90–38.00) 
Heart Rate (beats/min) 89.00 (82.00–100.00) 97.50 (80.00–110.00) 90.00 (82.00–100.00) 
Prior or concomitant treatments 
Lopinavir–ritonavir 86 (100) 40 (100) 126 (100) 
Antibiotics 86 (100) 40 (100) 126 (100) 
Interferon beta-1a 27 (31.40) 14 (35.00) 41(32.54) 
Hydroxychloroquine 26 (30.23) 13 (32.50) 39 (30.95) 
Favipiravir 13 (15.12) 3 (7.50) 16 (12.70) 
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substantially greater among critical patients compared with severe 
patients (log-rank test p-value  <  0.001) (Fig. 2). 
3.3. Other clinical outcomes 
Based on the six-point ordinal scale, median (IQR) score of oxygen- 
support class decreased from 3 (2–3) in day one to 1 (1–3) in day seven 
(p-value  <  0.001) and to 1 (1–1) in day 14 (p-value  <  0.001) in 
severe patients. The median (IQR) of change after 14 days of tocili-
zumab injection was −2 (−1 to −2), which means a median of two 
stage-reduction in the level of oxygen-support for individual patients. In 
critical patients, the median (IQR) score of oxygen-support class in days 
1, 7, and 14 were 4 (4–5), 5 (3–6), 6 (1–6), respectively. No statistically 
significant change occurred after 7 days (p-value = 0.572) and 14 days 
(p-value = 0.577) of the study initiation. The median (IQR) of change 
after 14 days of tocilizumab injection was 1 (−3 to 2). 
Median (IQR) oral temperature decreased significantly from 37.1 °C 
(36.8–38.0) to 36.9 °C (36.5–37.0) in severe patients (p-value  <  
0.001) and from 37.7 °C (37.0–39.0) to 37.0 °C (36.7–37.2) in critical 
patients (p-value = 0.006) from baseline through the last day of hos-
pital stay (Fig. 3A). Considering only the patients with a follow-up 
duration of three days or more, significant reduction in oral tempera-
ture was observed as early as three days in both severe patients (median 
(IQR) oral temperature, 37.1 °C (36.8–38.0) to 37.0 °C (36.6–37.0), p- 
value  <  0.001) and critical patients (median (IQR) oral temperature, 
37.8 °C (37.0–39.0) to 37.1 °C (37.0–37.6), p-value = 0.019). Median 
(IQR) respiratory rate decreased significantly from 20 breaths/min 
(19–24) to 18 breaths/min (18–20) in severe patients (p-value  <  
0.001) and from 24 breaths/min (20–26) to 17 breaths/min (15–21) in 
critical patients (p-value  <  0.001) from baseline through the last day 
of hospital stay (Fig. 3b). Considering only the patients with a follow-up 
duration of three days or more, considerable reduction in respiratory 
rate was observed as early as 3 days in both severe patients (median 
(IQR) respiratory rate, 20 breaths/min (18–22) to 20 breaths/min 
(18–22), p-value = 0.048) and critical patients (median (IQR) re-
spiratory rate, 24.5 breaths/min (20–26) to 20 breaths/min (20–24), p- 
value = 0.080). Median (IQR) SpO2 increased significantly from 90.0% 
(86.0–92.0) to 94.5% (93.0–96.0) in severe patients (p-value  <  0.001) 
and from 88.5% (80.0–90.0) to 93.0% (88.0–95.5) in critical patients 
(p-value = 0.022) from baseline through the last day of hospital stay 
(Fig. 3c). Considering only the patients with a follow-up duration of 
three days or more, significant increase in oxygen saturation was ob-
served as early as 3 days in both severe patients (median (IQR) SpO2, 
90.0% (86.0–92.0) to 93.0% (90.0–95.0), p-value  <  0.001) and cri-
tical patients (median (IQR) SpO2, 85.0% (78.5–90.0) to 89.5% 
(85.0–92.3), p-value = 0.021). 
3.4. Safety 
No tocilizumab-related serious adverse event occurred in the study 
subjects. Cardiac arrest (23.33%, 7/30), respiratory arrest (10.00%, 3/ 
30), ARDS and disease progression (23.33%, 7/30), brain injury 
(6.67%, 2/30), shock and septic shock (6.67%, 2/30), sepsis (3.33%, 1/ 
30), emphysema (3.33%, 1/30), cardio-respiratory arrest (3.33%, 1/ 
30), multiple organ dysfunction syndrome (3.33%, 1/30), organ failure 
(3.33%, 1/30), disseminated intravascular coagulation (3.33%, 1/30), 
gastrointestinal haemorrhage (3.33%, 1/30), intra-abdominal haema-
toma (3.33%, 1/30), and overdose (non-prescription opioid) (3.33%, 1/ 
30) were the preferred terms documented by study centers for the 30 
deaths occurred in this study. Other reported adverse events were in-
creased serum levels of creatinine (sCr) (7.14%, 9/126), alanine ami-
notransferase (ALT) (6.35%, 8/126), and aspartate aminotransferase 
(AST) (4.76%, 6/126), hypertension (1.59%, 2/126), blister (0.79%, 1/ 
126), oral herpes (0.79%, 1/126), and shock (0.79%, 1/126). 
3.5. Laboratory data 
Median (IQR) serum levels of WBC increased substantially in both 
severe patients (from 6.90 k/mm3 (5.15–9.08) to 7.71 k/mm3 
(5.43–12.02), p-value = 0.008) and critical patients (from 10.30 k/ 
mm3 (8.30–13.60) to 10.50 k/mm3 (8.41–19.21), p-value = 0.009) 
from baseline through the last day of hospital stay. Median (IQR) serum 
levels of CRP, an acute phase reactant, decreased in severe patients 
(from 22.00 mg/L (6.00–39.00) to 3.20 mg/L (1.00–13.00), p- 
value  <  0.001) and critical patients (from 48.00 mg/L (6.00–85.20) to 
20.00 mg/L (2.50–54.00), p-value = 0.689) from baseline through the 
last day of hospital stay. Changes in serum levels of other laboratory 
measures, including AST, ALT, sCr, partial thromboplastin time (PTT), 
and international normalized ratio (INR) are provided in Table A1. 
Fig. 2. Kaplan-Meier survival estimates in patients with severe and critical COVID-19.  
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Fig. 3. Changes in body temperature (A), respiratory rate (B), and oxygen saturation (C) in the two groups of patients from baseline through the last day of hospital 
stay. *p-value  <  0.05; **p-value  <  0.01; ***p-value  <  0.001. 
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4. Discussion 
An accentuated host immune response to SARS-CoV-2 leads to lung 
damage and respiratory failure in severe and critical stages of COVID- 
19. Despite the very poor prognosis of these patients, no im-
munomodulatory agent is yet approved for routine clinical practice in 
COVID-19 patients. Different studies report a very wide range of mor-
tality rates in severe and critical patients, from 0% [48] to 84.6% [49]. 
We observed a mortality rate of 6.98% (6/86) in patients with severe 
disease, which is close to 7.7% (7/90) reported by De Rossi et al. [39] in 
tocilizumab-treated patients with respiratory failure following SARS- 
CoV-2 infection. With a retrospective cohort design, they have included 
patients with severe pneumonia with a similar definition to that of our 
study. The authors reported a significantly better survival rate in pa-
tients treated with tocilizumab compared to those who received SOC 
only (multivariate hazard ratio: 0.057; 95% C.I. = 0.017–0.187, p- 
value  <  0.001). They have excluded patients with a critical respiratory 
condition requiring either invasive or noninvasive mechanical ventila-
tion, while we have evaluated these patients as a distinct group of 
subjects. The overall mortality rate in our critical patients was 60.0% 
(24/40), far more than the severe patients (p-value  <  0.001). Based on 
a recently published meta-analysis [50], the combined mortality rates 
in ICU admitted patients were 59.5% (calculated using the studies to 
the end of March 2020) and 41.6% (calculated using all eligible stu-
dies); however, the criteria for ICU admission were different in the 
included studies. In an observational controlled trial on 154 mechani-
cally ventilated COVID-19 patients, tocilizumab was associated with an 
increased incidence of superinfection compared to the control (54% vs. 
26%, p-value  <  0.001). However, the mortality risk did not differ 
significantly among tocilizumab-treated patients with and without su-
perinfection (22% vs. 15%, p-value = 0.42), and tocilizumab was as-
sociated with a significant reduction in mortality compared to the 
control (hazard ratio of 0.55 and 95% CI of 0.33–0.90) [51]. 
Collectively, on the one hand, our encouraging results in severe patients 
and on the other hand, the poor survival rate in critical patients con-
firms the rationale of De Rossi et al. for considering tocilizumab at the 
early stages of respiratory failure, before the development of a critical 
condition requiring assisted mechanical ventilation, and not when the 
lung damage has already occurred. 
To date, none of the randomized controlled trials of tocilizumab in 
COIVD-19 are published; however, the interim results of the CORIM-
UNO-TOCI (#NCT04331808) trial were announced through a press 
release on 27 April 2020, and Roche provided a summary of the find-
ings of the COVACTA (#NCT04320615) trial on 29 July 2020 [43,52]. 
According to the preliminary results of the CORIMUNO-TOCI trial, 
8 mg/kg intravenous administration of tocilizumab significantly re-
duced the probability of death or need for ventilation compared to the 
SOC treatment alone. However, in the COVACTA trial, only a positive 
trend in the time to hospital discharge was observed in the tocilizumab 
group, and the trial did not meet the main endpoints of significant 
improvements in clinical status and survival rate. The interim report of 
CORIMUNO-TOCI only considered patients who did not require venti-
lator support at the beginning of the trial. In contrast, according to the 
unpublished manuscript of COVACTA [53], 70.4% (207/294) of toci-
lizumab-treated patients were ventilator-dependent at the baseline of 
this study. Altogether, the promising results of CORIMUNO-TOCI, along 
with our positive results in severe patients and low survival rates in 
critical patients, highlight the importance of appropriate timing in the 
administration of tocilizumab in COVID-19. 
In our study, rapid and consistent improvements in body tempera-
ture, respiratory rate, and blood oxygenation were observed as early as 
three days post-tocilizumab and sustained thereafter. As IL-6 is an im-
portant component of the so-called “cytokine storm” following SARS- 
CoV-2 infection, rapid amelioration of the clinical measures of disease 
severity in a significant proportion of patients could be attributed to the 
inhibition of IL-6-mediated signaling by tocilizumab. These results are 
Fig. 3.  (continued)  
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consistent with those of three relatively small studies in China (15 
subjects) [54], Qatar (25 subjects) [55], and Italy (63 subjects) [40], in 
which satisfactory changes in body temperature, respiratory para-
meters, and inflammatory markers were observed a short time after 
tocilizumab administration. Similarly, in a prospective study of 100 
severe COVID-19 patients in Italy, a rapid improvement of the clinical 
condition occurred in most (58%) of the patients within 12–72 h after 
tocilizumab administration. Moreover, the authors reported sustained 
clinical benefit in all patients with an initial clinical response through 
the end-of-study follow-up (day 10) [56]. 
We reported significantly improved levels of required oxygen-sup-
port class in severe patients in days seven and 14 post-tocilizumab. 
Fernández-Ruiz et al. [57], in a retrospective analysis of 88 patients 
with severe COVID-19 pneumonia, reported a declined level of required 
oxygen therapy in the majority of patients (73.9%) by day 14. Similarly, 
Alattar et al. [55], in a retrospective study of 25 severe COVID-19 pa-
tients, reported a considerable reduction in the proportion of patients 
on invasive ventilation from 84% at baseline to 60% and 28% on days 
seven and 14 post-tocilizumab, respectively. During this pandemic, 
intensive care units around the world are overrun by the huge number 
of critically ill patients, and hospitals are struggling with shortages in 
resources such as mechanical ventilators [58]. This situation highlights 
the benefits of a treatment that ameliorates the oxygen-support re-
quirements and reduces the need for ICU admission. 
Our study was performed using the subcutaneous dosage form of 
tocilizumab (162 mg/ 0.9 mL) with a dose of 324 mg (in patients 
weighing below 100 kg, n = 120) or 486 mg (in patients weighing 
100 kg or more, n = 6). This dosing schedule is similar to many other 
studies that used subcutaneous tocilizumab in COVID-19 patients  
[38–40]. While the intravenous dosage form is generally considered for 
the cytokine release syndrome [59], the subcutaneous injection was 
used in our study centers and many others around the world due to the 
unavailability of the intravenous tocilizumab. A pharmacokinetic/ 
pharmacodynamic study found comparable effects of 162 mg tocili-
zumab on serum levels of soluble IL-6 receptor (sIL-6R) and CRP either 
using a subcutaneous or intravenous injection in healthy volunteers and 
concluded that the 162 mg subcutaneous and intravenous tocilizumab 
are pharmacodynamically equivalent [60]. Moreover, in the only 
pharmacokinetic study of 324 mg subcutaneous tocilizumab, the area 
under the concentration-time curve (AUC) of the 4 mg/kg intravenous 
tocilizumab (during a 4-week interval) was found to be close to that of a 
single-dose 324 mg subcutaneous injection (13,000  ±  5800 and 
10,800  ±  3220 μg.h/mL, respectively) [61]. These two studies (per-
formed by the same groups) found higher absolute pharmacokinetic 
bioavailability of tocilizumab with higher subcutaneous doses; 22.7% 
with 81 mg, 48.8% with 162 mg, 75.9% with 324 mg, and 83.0% with 
648 mg injections. Collectively, it could be concluded that 324 mg 
subcutaneous tocilizumab (and 486 mg in subjects with heavier body-
weight) is a reasonable substitute for the 4–8 mg/kg intravenous toci-
lizumab, which is the recommended dose by the China National Health 
Commission [62] and is used in clinical studies [22,63]. In the study 
protocol of several randomized controlled trials of tocilizumab in 
COVID-19, infusion at a dose of 8 mg/kg is considered for all partici-
pants [43,53,64–66]. Hence, as 648 mg subcutaneous tocilizumab is 
considered equivalent to 8.23 mg/kg by Morcos et al. [61], doses higher 
than 324/468 mg subcutaneous tocilizumab could also be considered in 
the future studies. In previous studies on patients with severe COVID- 
19, no difference was observed between the benefits of subcutaneous 
and intravenous tocilizumab on mortality rates. Guaraldi et al. [38] 
reported mortality rates of 7.7% (7/91) and 6.8% (6/88), and Sciascia 
et al. [40] reported mortality rates of 10.3% (3/29) and 12.9% (4/31) 
with subcutaneous and intravenous tocilizumab, respectively. These 
two routes of administration of tocilizumab are generally known to 
have similar safety profiles with the only exception of a higher risk of 
injection site reactions with the subcutaneous form [67,68]; however, 
no injection site reaction was reported in our study, which could be 
because of the small number of injections per patient. Accordingly, 
based on the available information on the pharmacokinetic/pharma-
codynamic and safety profiles of subcutaneous and intravenous tocili-
zumab and the clinical efficacy results of the above-mentioned studies 
in COVID-19 patients, a similar clinical response would be expected 
with the two formulations of tocilizumab. 
Uncontrolled design is the main limitation of our study. Without a 
control group, we cannot have certainty on the interpretation of our 
observations. This limitation would be specifically important in this 
pandemic situation, as surges in the number of hospitalized COVID-19 
patients put major pressure on healthcare systems and may result in the 
presence of different confounders in different study settings. Despite 
this limitation, our study furthers the available evidence on the use of 
tocilizumab in severe and critical COVID-19 patients. Moreover, our 
data represents the largest published study on subcutaneous use of to-
cilizumab in COVID-19 and, even more generally, in patients with the 
cytokine-release syndrome. 
In summary, we observed significant improvements in some clinical 
parameters of our COVID-19 patients following the subcutaneous ad-
ministration of tocilizumab. Looking at the mortality rates of severe and 
critical patients, it can be concluded that subcutaneous tocilizumab 
might be capable of reducing the risk of death, particularly if used in 
the early stages of respiratory failure. The final results of the ongoing 
randomized controlled trials of tocilizumab for COVID-19 are needed to 
complement the available data on the safe and effective use of tocili-
zumab in COVID-19. 
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Appendix A 
See Fig. A1 and Table A1. 
Table A1         
Baseline measurement Last measurement p-value  
WBC (k/mm3) Severe 6.90 (5.15–9.08) 7.71 (5.43–12.02) ** 0.008 
Critical 10.30 (8.30–13.60) 10.50 (8.41–19.21) ** 0.009  
CRP (mg/L) Severe 22.00 (6.00–39.00) 3.20 (1.00–13.00) ***  < 0.001 
Critical 48.00 (6.00–85.20) 20.00 (2.50–54.00) 0.689  
ALT (IU/L) Severe 36.50 (24.50–62.00) 57.00 (35.50–115.00) ***  < 0.001 
Critical 46.00 (28.00–61.00) 54.00 (43.00–66.00) 0.232  
AST (IU/L) Severe 35.00 (25.00–49.00) 44.00 (27.00–71.00) 0.171 
Critical 49.00 (36.00–82.00) 50.00 (33.00–78.00) 0.925  
sCr (mg/dL) Severe 1.00 (0.90–1.10) 0.90 (0.80–1.00) 0.061 
Critical 1.10 (0.90–1.20) 1.08 (0.90–1.70) 0.584  
PTT (s) Severe 38.00 (30.00–43.00) 31.00 (27.00–36.00) ***  < 0.001 
Critical 36.00 (34.00–39.00) 33.00 (22.00–40.00) 0.191  
INR Severe 1.14 (1.07–1.23) 1.12 (1.02–1.22) 0.132 
Critical 1.29 (1.19–1.40) 1.20 (1.10–1.35) 0.253 
Changes in laboratory values in the two groups of patients from baseline through the last day of hospital stay. Data are median (Q1-Q3). ALT, alanine amino-
transferase; AST, aspartate aminotransferase; CRP, C-reactive protein; INR, international normalized ratio; PTT, partial thromboplastin time; sCr, serum creatinine; 
WBC, white blood cell. **p-value  <  0.01; ***p-value  <  0.001.  
Fig. A1. Individual participant’s time-to-event data in critical (A) and severe (B) patients from the day of tocilizumab injection through hospital discharge or death.  
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Appendix B. Supplementary material 
Supplementary data to this article can be found online at https://doi.org/10.1016/j.intimp.2020.107102.  
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